Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

John Doster (NPI 1982670147)

Field	Value
Entity Type	Individual
Organization	John Doster
Address	2000 E Greenville St
City	Anderson
State	SC
ZIP	29621
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 27, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider’s Medicare activity is concentrated in oncology therapeutics and infusion services: the largest revenue codes are J9271 (pembrolizumab), J0897 (denosumab), and Q5119 (rituximab biosimilar), and the precomputed top-3 Medicare codes account for 70.4% of the provider’s total Medicare revenue. The mix of high-volume biologic and chemotherapy administration codes (including 96413, 96417, 96365) indicates the practice primarily delivers cancer-directed infusion therapy and related supportive care.

Revenue concentration on Medicare is heavy: total Medicare revenue is $2.3M and the top three codes alone make up 70.4% of that amount. This concentration shows the practice derives most of its Medicare payments from a small set of high-cost oncology drugs and infusion procedures rather than from office E/M or broad diagnostic testing.

Payer mix is effectively single-payer: Medicare revenue of $2.3M is on file but there is no Medicaid billing on file, so the provider operates as a Medicare-only biller in the available data. Analysts should treat this profile as focused on the Medicare population and not representative of dual-payer delivery.

Competitive standing varies by code: for J9271 the provider ranks #149 of 1841 (92nd percentile) indicating typical, unremarkable national volume for pembrolizumab, whereas for J0897 the provider ranks #434 of 10057 (96th percentile), and for Q5119 the provider ranks #15 of 335 (96th percentile), both described as notably above typical national volume. These ranks suggest the provider is a relatively high-volume administrator of denosumab and the rituximab biosimilar compared with national peers, while pembrolizumab volume is more typical.

Several infusion- and chemotherapy-related CPTs are reported at notably above-typical or extreme national volumes: 96413 (ranked in the 98th percentile), 96417 (96th percentile), 96375 (98th percentile), and 96367 (95th percentile) are all described as notably above typical national volume. This consistent pattern across multiple administration add-on and infusion codes supports the view that infusion throughput is a central operational activity for the practice.

Office E/M and outpatient visit billing is substantial relative to many peers: 99214 and 99215 appear with $101.8K and $78.8K in Medicare revenue respectively, and both are listed as extreme outliers or far above typical national volume (99214 at the 98th percentile described as an extreme outlier; 99215 at the 99th percentile). High-volume established-patient E/M visits alongside heavy infusion coding suggests the provider manages ongoing oncology patients longitudinally rather than only administering episodic infusions.

Lab and monitoring services are present but represent a small share of revenue: multiple lab panels and tumor marker tests (80053, 85025, 83615, 83735, 86300, 82378) appear across the top codes but each individually contributes around 0.3–1.1% of Medicare revenue and are generally described as typical or notably above typical volume. This mix is consistent with routine labs and cancer surveillance that support an infusion-focused oncology practice.

Tenure: the provider’s NPI was enumerated on 2006-02-27 (~20 years ago), indicating long-standing enrollment and likely sustained operations in the market. That tenure, combined with concentrated high-volume infusion codes, suggests an established oncology practice with persistent treatment volumes over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

74 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	28,200	$40	$1.2M
J0897	Injection, denosumab, 1 mg	16,500	$20	$297K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	4,680	$20	$112.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,130	$90	$101.8K
J1439	Injection, ferric carboxymaltose, 1 mg	98,250	$1	$98.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	850	$100	$80.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	600	$130	$78.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	740	$90	$68.4K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	2,550	$10	$25.5K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	3,030	$10	$24.3K

Showing 1–10 of 74

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 74 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

John Doster — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

74 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	30	19,700	$40	$832K
Q5119	1	10	4,680	$20	$110.8K
J0897	16	250	2,400	$20	$91.2K
J3490	16	50	70	$510	$57.7K
J2506	7	10	740	$80	$55.9K
J1439	4	30	42,750	$1	$42.3K
99214	283	7,860	160	$80	$23.2K
J9217	33	70	130	$130	$22.1K
96413	5	150	140	$90	$22.1K
99232	2,446	2,780	90	$60	$12K

Showing 1–10 of 74

Related Providers

Other providers that share a Tax Identification Number (TIN) with John Doster, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
James Mcclain	SC	Hematology & Oncology Physician	$2M	$0
Jay Nayak	SC	Hematology & Oncology Physician	$1.4M	$0
Britt Bolemon	SC	Hematology & Oncology Physician	$234.6K	$0

Nearby Providers

Other providers in the same ZIP code as John Doster, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Anmed Health	SC	General Acute Care Hospital	$0	$75.9M
Palmetto Seating And Mobility, Inc.	SC	Durable Medical Equipment & Medical Supplies	$0	$44.7M
South Carolina Dept Of Mental Health Accounting Office	SC	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$40.9M
Creston Dental-1, P.C.	SC	General Practice Dentistry	$0	$14.8M
Southern Home Care Services, Inc.	SC	In Home Supportive Care Agency	$0	$14.1M
Medshore Ambulance Service, LLC	SC	Ambulance	$6.4M	$7M
Bryant Pharmacy & Supply	SC	Durable Medical Equipment & Medical Supplies	$0	$11.4M
Labtech Diagnostic, LLC	SC	Clinical Medical Laboratory	$0	$10.7M
Anmed Health	SC	Pediatrics Physician	$0	$10.3M
Upstate Medical Staffing, Inc.	SC	In Home Supportive Care Agency	$0	$9.3M

John Doster — Billing Profile & Reimbursement Data

Sign up for John Doster — Billing Profile & Reimbursement Data policy alerts

John Doster — Billing Profile & Reimbursement Data

Sign up for John Doster — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References